Key result
Carriers of the ET(A)T allele in the ETA receptor gene had a significantly higher risk of death within 2 years of dilated cardiomyopathy diagnosis compared to non-carriers (OR 5.5; 95% CI 1.4-21.0; P=0.013).
Why the study?
Does the ETA H323H polymorphism predict survival in patients with idiopathic dilated cardiomyopathy?
Cohort (n=125)
Does the ETA H323H polymorphism predict survival in patients with idiopathic dilated cardiomyopathy?
Odds Ratio: 5.5 (95% CI 1.4–21)
p-value: p=0.013
The ETA H323H polymorphism is an independent predictor of shorter survival in patients with idiopathic dilated cardiomyopathy, potentially aiding in identifying high-risk individuals.
ETA H323H polymorphism was associated with higher 2-year mortality in idiopathic DCM; hypothesis-generating for genetic risk stratification pending validation.
AIMS: The endothelin system plays a role in the complex pathophysiology of idiopathic dilated cardiomyopathy. We investigated whether genetic polymorphisms of the endothelin system might be associated with dilated cardiomyopathy-related cardiac phenotypes and differences in disease outcome. METHODS: One hundred and twenty-five unrelated dilated cardiomyopathy patients of a well characterized dilated cardiomyopathy cohort were genotyped for six common polymorphisms of the endothelin-1, endothelin-A (ETA) and endothelin-B (ETB) receptor genes using hybridization with allele-specific oligonucleotides. RESULTS: The H323H (C/T) polymorphism in exon 6 of the ETA receptor gene was significantly associated with a shorter survival time after diagnosis. The odds ratio for carriers of the less frequent ET(A)T allele to die within 2 years after diagnosis was 5.5 (95% confidence interval, 1.4 to 21.0, P=0.013) compared to non-carriers. Kaplan-Meier analysis revealed a significantly different survival time for T allele carriers as compared to non-carriers as tested by logrank (P=0.0196), Breslow (P=0.0195), and Tarone tests (P=0.020). The influence of the ETA H323H polymorphism on survival remained significant when known predictors of prognosis such as left ventricular ejection fraction, left ventricular end-diastolic diameter, age and NYHA functional classification were entered in a Cox proportional hazards analysis. In this model, end-diastolic diameter showed a trend to influence survival (P=0.07) but only the ETA H323H polymorphism (P=0.0029) was a significant independent predictor of survival. CONCLUSIONS: Our results suggest that genetic variation in the ETA receptor predicts survival in dilated cardiomyopathy patients, which might have important consequences for the identification of high-risk individuals.
No takes yet. Share an insight, caveat, or question.
Stefan-Martin Herrmann (2001) conducted a cohort in Idiopathic dilated cardiomyopathy (n=125). ET(A)T allele of the ETA receptor gene H323H (C/T) polymorphism vs. Non-carriers was evaluated on Death within 2 years after diagnosis (OR 5.5, 95% CI 1.4 to 21.0, p=0.013). Carriers of the ET(A)T allele in the ETA receptor gene had a significantly higher risk of death within 2 years of dilated cardiomyopathy diagnosis compared to non-carriers (OR 5.5; 95% CI 1.4-21.0; P=0.013).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: